Ubiquitin is a highly conserved, small polypeptide that is covalently linked to protein substrates targeted for intracellular modification. Conjugation by ubiquitin alters protein function and stability with important roles in various biological processes, such as regulation of the cell cycle, response to DNA damage, intracellular trafficking and surveillance of protein quality. A sequential enzymatic cascade transfers ubiquitin to its target, with an E3 ligase catalyzing the final step: a covalent linkage to the ε-amino group of a lysine residue or an N-terminal methionine of the substrate 1-4 . Despite considerable efforts, the identification of substrates for specific ubiquitin ligases remains a challenge.
ligases in both budding yeast and mammalian cells. Purified substrates are subjected to MS analysis.
Advantages and applications of ligase traps
Ligase trapping allows for the reliable identification of protein ubiquitination in vivo. The protocol is fast and relatively straightforward, and the purification scheme takes ~2-3 d to complete. The efficiency and reliability of this method make this procedure generally accessible to most laboratories. This technique can be easily applied to many ubiquitin ligases, and it will prove useful in the identification of novel substrates. One advantage of ligase trapping is its high specificity and low background. Indeed, our MS analysis detected zero peptides for most off-target ligases in our yeast purifications 22 . Another advantage lies in the ability to use ligase trapping to validate substrates in follow-up experiments. For example, smaller-scale cultures can be used to visualize substrate ubiquitination via western blot analysis. Finally, ligase trapping can be performed under various perturbations, such as environmental stress or chemical agents, which may alter the repertoire of substrates for certain ligases.
Limitations of ligase traps
As with any biochemical method, there are a number of caveats that must be considered when you are using ligase traps. First, a ligase may not be amenable to protein fusion at either terminus (i.e., yeast Hrd1), and doing so may disrupt its ability to target its biological substrates. Second, ligase trapping is a stoichiometric procedure, and lower-affinity substrates will be identified with fewer spectral counts, although one spectral count is sufficient for identification. Furthermore, the UBA domains described here have not been well characterized for their ability to bind atypical polyubiquitin chains, such as K11-or K33-linked ubiquitin, so we cannot attest to their success in capturing substrates modified with these chain types. Ligase trapping is optimal for the identification of substrates of specific ligases and, unlike more global approaches, it is not designed for analysis of the total ubiquitinated proteome. The limiting factor for scaling up this method is the workload required to generate additional UBA-fusion constructs for each ligase to be screened.
Comparison with alternative protocols
Numerous protocols have been developed that rely on tandem affinity purifications to capture physical interactors of ubiquitin ligases [23] [24] [25] . Strategies have been developed independently for the isolation of ubiquitinated proteins from cells based on the overexpression of tagged ubiquitin combined with at least one denaturing purification step to reduce nonubiquitinated interactors [26] [27] [28] [29] [30] [31] [32] [33] . Alternatively, studies have used immobilized poly-ubiquitin-binding domains (poly-UBDs) to isolate endogenously ubiquitinated proteins [34] [35] [36] [37] [38] [39] . Our ligase trap method combines elements from each of these protocols, namely the enrichment capacity of tandem affinity ligase purification, with the added selectivity for polyubiquitinated proteins via 6×His-ubiquitin denaturing purifications and fusion with UBDs.
Other MS-based approaches that enable the identification of ubiquitinated substrates of specific ligases have been published. Most of these exploit the physical association of substrates with their respective ligases, whereas some take a more global approach to identifying ubiquitinated peptides.
The Parallel Adapter Capture (PAC) technology developed by Harper and colleagues 40 uses comparative MS to analyze immunopurified ligase adapter proteins in the presence or absence of proteasome or NEDD8 inhibition. Compared with ligase trapping, this method is similar in that it also enables the identification of substrates for a specific ligase adapter, as opposed to a family of adapters or ligases. Similarly, it can identify substrates of low abundance, as a single peptide is sufficient for identification. Both protocols rely on the identification of interactors that are specific to a particular ligase by comparing MS results for many different ligases, either using the Comparative Proteomics Analysis Software Suite (CompPASS), for PAC 41, 42 , or a similar method that compares each ligase trap IP with all other ligase trap IPs done in the same organism within our laboratory 22, 43 . A notable difference between the two protocols is that ligase trapping greatly enriches for substrates, whereas PAC does not distinguish substrates from other stably interacting proteins. Further, ligase trapping provides a way to validate candidate substrates, as ubiquitinated species of substrate proteins can be purified by the ligase trap construct and visualized by western blot analysis. A comparison of our recent analysis of substrates of the human F-box β-transducing-repeat-containing protein (β-TrCP) 43 with a similar study that used PAC 44 shows the relative strengths of these techniques. For the well-studied F-box protein β-TrCP, ligase trapping identified 28 unique interactors, of which 12 were known substrates. We attempted to validate 14 of the novel substrates, and we successfully purified ubiquitinated species of 11 of these. By using PAC to study the same ligase, Kim et al. 44 identified 151 interactors, of which 16 were previously known substrates. They tested whether nine of the novel interactors that they identified were actually β-TrCP substrates, and the showed that three were stabilized by β-TrCP knockdown and that two additional substrates bound to β-TrCP only in the presence of the proteasome inhibitor MG132, and thus they are probable substrates. We used ~10 9 cells for each MS experiment, whereas a typical PAC protocol
Substrate S u b s t r a t e Substrate Second step First step Figure 1 | Overview of the ligase trapping procedure. F-box-UBA domain fusion proteins (i.e., ligase traps) are expressed in cells at physiological levels along with overexpression of a single copy of the ubiquitin gene containing an N-terminal hexahistidine epitope tag. The UBA of the ligase trap interacts with the nascent ubiquitin chain on endogenous SCF substrates, thereby delaying their release (left). Cells are then lysed and subjected to an anti-FLAG coimmunoprecipitation under native conditions to isolate ligase trap complexes (center). FLAG eluates are collected and a second purification is performed using Ni-NTA agarose beads under denaturing conditions to capture ubiquitinated substrates (right). This second step eliminates interactors associated with the ubiquitinated species that are not themselves substrates. FL, FLAG; H, histidine. uses 10 7 cells 40 . Thus, experiments published so far suggest that a far higher percentage of the interactors discovered by ligase trapping are bona fide substrates, whereas PAC may discover a slightly higher number of true substrates and requires substantially less material.
Ubiquitinated peptides can be identified via MS detection of Gly-Gly (di-GLY) residues that arise after trypsinization of ubiquitinated samples 26, [45] [46] [47] . Recently, this technology has been adapted to identify ligase substrates by comparing the repertoire of diGLYmodified peptides after genetic or chemical perturbation of a particular ligase [48] [49] [50] . These studies identified comparable numbers of substrates as ligase trapping. However, this approach suffers reproducibility issues for low-abundance targets, because of stochastic sampling 51 , and, as mentioned earlier, altering the function or abundance of a given ligase may lead to nonphysiologic results.
Experimental design
Generation and growth of ligase trap yeast strains. This protocol requires a yeast strain that expresses both (ii) galactose-inducible 6×His-tagged ubiquitin and (ii) an F-box protein fused to a UBA domain via a 3×FLAG linker sequence. To generate the latter construct, we used the integrating vector pRS306 to clone the DNA in the following order: a partial C terminus of an F-box protein, a 3×FLAG linker sequence and either the two C-terminal UBA domains of the RAD23 gene (codons 143-397) or the single UBA domain of the DSK2 gene (codons 327-373). To integrate the ligase trap into its endogenous locus, the plasmid was linearized at a unique restriction site in the DNA encoding the F-box protein and transformed into yeast cells. Ligase traps with the UBA domain fused to the N terminus of the F-box protein were also created (promoter-UBA-3×FLAG-F-box). To overexpress 6×His-ubiquitin, we inserted the His3MX-GAL1-6×His cassette upstream of the last ubiquitin sequence in the UBI4 locus (which contains five ubiquitin sequences in tandem), thus deleting the UBI4 promoter. Colonies were checked by PCR, and we selected a strain containing only a single remaining copy of ubiquitin tagged with 6×His under the GAL1 promoter. The tagged ubiquitin is expressed at a high level upon growth in galactose, such that at least 50% of the total ubiquitin in the cell is tagged. To express sufficient levels of 6×His-ubiquitin, yeast cell lines in log phase are grown in galactose for slightly less than two doubling times before collection, lysis and two-step immunoprecipitation.
Generation and growth of ligase trap-stable mammalian cell lines. To produce an analogous stable mammalian cell line, we integrated three constructs into 293 FlpIn TRex cells. 293 FlpIn TRex cells already express the tet repressor; therefore, genes whose promoter sequences contain the tet operator are expressed only upon the addition of doxycycline. Into these cells, we first tranfected a linearized plasmid encoding doxycycline-inducible 6×His-ubiquitin marked with neoR, selected clonal stable cell lines and screened for those with the highest doxycycline-inducible 6×His-ubiquitin expression, such that tagged ubiquitin represents at least one-quarter of the total ubiquitin pool upon doxycycline treatment. Next, we transfected this stable cell line with a linearized plasmid encoding both an shRNA against the endogenous ubiquitin ligase of interest and an shRNA-resistant version of this ligase fused to 3×FLAG and the C terminus of RAD23B (codons 185-409), which contains two UBA domains; this plasmid was marked with hygromycin resistance. We selected hygromycinresistant clonal cell lines and screened for those that both repressed the endogenous ligase (where this was possible to ascertain) and expressed the ligase trap at near-endogenous levels, as measured by western blotting. For ligases for which no antibody was available, we compared the expression of the ligase trap with the expression of another ligase trap for which an antibody was available, and we calculated the appropriate expression level on the basis of the relative message levels of the two ligases in HEK293 cells (see Sultan et al. 52 ).
Efficient identification of ubiquitin ligase substrates using this technique requires a large number of cells: 63 just-subconfluent 245 × 245 mm dishes. As mentioned earlier, this is substantially more cells than are used in similar techniques: we use ~10 9 cells, whereas Harper and colleagues' PAC protocol uses 10 7 cells 40 . The larger initial input in our protocol is probably required because our two-step purification only captures the small pool of any substrate that is ubiquitinated at the moment of cell lysis. However, two repeats of each purification are typically sufficient to identify substrates. Cells are treated with MG132 for 4 h before collection, lysis and immunoprecipitation.
Proteomic conditions. As with all proteomics, care should be taken to avoid keratin contamination of samples, as this will interfere with the detection of substrate peptides. For reagent preparation, we recommend the following precautions: Sample monitoring. Before MS analysis, it is useful to collect a small quantity of each eluate for western blotting and silver staining to estimate the efficiency of purification. This is noted in Steps 1A and 1B(x, xiii,xvi,xvii,xix).
Timing. To produce a protein sample for MS analysis from saturated liquid yeast cultures or confluent tissue culture plates, it takes ~2.5 or 5 d, respectively. After data collection, processing of the results obtained can take markedly longer.
Future directions. Ligase trapping works very well for some ubiquitin ligases (e.g., Grr1 and β-TrCP), and it works less well for others, such as Hrd1, Cdc20 and Fbw7). The identification of substrates for some ligases may be improved by optimization of the ligase trap. Ubiquitin ligases may be fused to the UBA domain on the opposite end, fused to a different UBA domain or expressed at a higher level. We will determine whether the efficacy of this protocol is increased by the use of UBA domains with increased affinities for polyubiquitin chains, such as tandem
ubiquitin-binding entities 37 , or by the use of linkage-specific polyubiquitin-binding domains (i.e., TAB2 NZF for K63, NEMO UBAN for linear) 53, 54 . We are currently rebuilding ligase traps with 4-6 copies of the UBA. Although we were initially worried that high-affinity UBAs might nonspecifically pull down polyubiquitinated proteins, this does not appear to be a problem when ligases are expressed at endogenous levels.
This protocol describes the use of UBA-ligase fusion proteins to identify substrates of the SCF family of ubiquitin ligases, but this work could be expanded to other families of ubiquitin ligases. In addition, other ubiquitin-like modifiers, such as SUMO or LC3, also have specific binding domains 55, 56 , and they can be used to generate an analogous enzyme 'trap' to search for target substrates. Remove the cap and fill the tube with ~50 ml of liquid nitrogen. Use a pipette to add the yeast sample, drop by drop, into the liquid nitrogen-containing tube, while refilling with liquid nitrogen to maintain at least a 30-ml volume. This creates frozen droplet-sized sample 'beads' . Place the screw cap back on and discard the liquid nitrogen through the slits. Alternatively, if you do not have access to a ball mill, we have had success lysing cells in a bead beater with glass beads. Divide the cell lysate into 1.5-ml screw-cap tubes.  crItIcal step Drop the sample into liquid nitrogen slowly to avoid clumps. Be careful when performing this procedure, as liquid nitrogen can cause severe burns. The use of a face shield is highly recommended.
MaterIals

REAGENTS
? trouBlesHootInG  pause poInt Sample 'beads' can be stored at −80 °C until required. (v) Transfer the sample 'beads' to a precooled steel ball mill chamber. Grind the sample with the ball mill using five cycles of 2 min at 27 Hz. Cool the chambers intermittently by submerging them in liquid nitrogen for 2 min between cycles. Alternatively, if you do not have access to a ball mill, add glass beads and agitate in a bead-beater six times for 1.5 min, resting 2 min on ice in between rounds.  crItIcal step Cool the chambers in liquid nitrogen before adding samples. Do not close the metal chambers too tightly; bubbles should appear when they are submerged. Apply safety precautions while handling liquid nitrogen. ? trouBlesHootInG (vi) Transfer the powder with a spatula that has been precooled in liquid nitrogen to a 50-ml Falcon tube and resuspend it in 10 ml of lysis buffer on a rocking platform at 4 °C. Make sure that the sample is thoroughly suspended (~2 h).
Transfer the sample to a 15-ml Falcon tube. Add 500 µl of DNase I (5,000 U) and incubate at 4 °C on a rocking platform for 30 min. Alternatively, if you have lysed the cells by bead beating, pool the lysate in a 15-ml Falcon tube and proceed with adding DNase I.  crItIcal step Precool the spatula in liquid nitrogen before use to prevent the sample from melting. (vii) Preclear the lysate by centrifuging it at 6,000g for 10 min at 4 °C using an Oak Ridge centrifuge tube. Transfer the supernatant to a new Oak Ridge tube and centrifuge it at 58,500g for 1 h at 4 °C. ? trouBlesHootInG (viii) Section 2: purification-stage I, native FLAG (12-16 h) . In a 15-ml Falcon tube, use the magnet of a six-tube magnetic stand to wash 380 µl of anti-FLAG magnetic bead slurry three times with 4 ml of lysis buffer containing 0.08% (vol/vol) Nonidet P-40.  crItIcal step Use wide-bore tips to avoid damaging the beads during pipetting. Mix the beads well before removal, as they settle quickly. (ix) (Optional) Take 5 µl of lysate and check the protein concentration with a BCA kit according to the manufacturer's instructions. (x) Save 30 µl of lysate (0.2%) for quality-control analysis ( Step 1A(xxi)). Add the lysate to the beads and incubate the mixture on a rotating platform overnight at 4 °C. Expect a total volume of ~15 ml. 
Box 1 | Variations to the protocol for validation of substrates
• Transform yeast strains or transiently transfect stable mammalian cell lines expressing the cognate ligase trap, or a negative control ligase trap, with a construct that expresses the candidate substrate fused to a repeating epitope tag for which a sensitive antibody exists, such as 13×Myc or 5×HA. Endogenous antibodies are often not sufficiently sensitive to detect the small pool of ubiquitylated substrate.
• Treating mammalian cells with MG132 before collection can increase background binding. Therefore, it is usually preferable not to use MG132 for validation. However, it may be necessary for some very unstable substrates.
• Use 350 OD 600 yeast cell pellets or one or two 245 × 245 mm plates of mammalian cells for each sample.
• Lyse each sample in 1.2 ml of lysis buffer (yeast) or 1 ml of lysis buffer per confluent 245 × 245 mm plate (mammalian cells).
• For yeast validation, load 0.006% of the input, 5% of the FLAG elution and 17% of the Ni-NTA elution. For mammalian cell validation, load 0.08% of the input, 2.5% of the FLAG elution and 50% of the Ni-NTA elution.
(iv) Pool the lysates and sonicate each sample three times for 5 s at 30% amplitude, resting them on ice between rounds.
(v) Add 100 µl of DNase I (1,000 U) and incubate the samples at 4 °C on a rocking platform for 30 min.
(vi) Add Nonidet P-40 to 0.1% (vol/vol) and mix the tube by inverting. Divide the samples into 2-ml tubes, and preclear the lysate by centrifuging at 20,000g for 15 min at 4 °C. Transfer the supernatant to a new 2-ml tube, and centrifuge it at 20,000g for 15 min at 4 °C. ? trouBlesHootInG (vii) Section 2: purification-stage I, native FLAG (12-16 h) . In a 15-ml Falcon tube, wash 100 µl of anti-FLAG magnetic bead 50% slurry three times with 1 ml of lysis buffer containing 0.1% (vol/vol) Nonidet P-40.  crItIcal step Use wide-bore tips to avoid damaging the beads during pipetting. Mix the beads well before removal, as they settle quickly. (viii) Take 5 µl of the lysate and check the protein concentration with a BCA kit according to the manufacturer's instructions.
We aim to use 100 mg of protein for each MS experiment. ? trouBlesHootInG (xv) Save 20 µl of FLAG eluate (3.5%) for quality-control analysis (Step 1B(xx)). Transfer the remainder of the FLAG eluate to the tube containing the Ni-NTA agarose beads. Add 1.14 ml of 1.5× buffer B and 17 µl of 1 M imidazole. Incubate the mixture at room temperature for 3.5 h on a rotisserie.  crItIcal step This step and all subsequent steps are done at room temperature. (xvi) Centrifuge the mixture at 800g for 3 min, and then carefully transfer the beads to a 1.5-ml low protein-binding tube.
Wash the beads three times with 1 ml of buffer B containing 10 mM imidazole. Centrifuge the beads at 800g for 3 min. Save 35 µl (3.5%) of the Ni-NTA flow-through for quality-control analysis (Step 1B(xx)).  crItIcal step For each wash, a new tube should be used to reduce the background. Use wide-bore pipette tips to avoid damaging the beads. Use a 25G × 1 1/2 needle to aspirate the supernatant and avoid picking up any beads. ? trouBlesHootInG (xvii) Wash the beads twice with 1 ml of Ni-NTA wash buffer containing 10 mM imidazole. Centrifuge the tube at 800g for 3 min to collect the beads after each wash.  crItIcal step For each wash, a new tube should be used to reduce the background. ? trouBlesHootInG (xviii) Elute the beads using 90 µl of Ni-NTA elution buffer. Vortex at room temperature for 20 min. To collect the eluate, place an Eppendorf GeLoader tip into the bead bed and gently remove the liquid by pipetting. Save 10 µl of imidazole elution (11%) for quality-control analysis (Step 1B(xx)) and freeze the remainder in liquid nitrogen for MS analysis.
? trouBlesHootInG (xix) Send the samples for MS analysis. Although some laboratories are capable of performing MS studies, most will choose to collaborate with others for this analysis or use the service of a protein chemistry core facility. (xx) Section 4: quality control after purification (1 d • tIMInG
Step 1A, yeast: 2. antIcIpateD results Figure 2 shows a representative western blot (Fig. 2a) of ligase trap purifications. Polyubiquitinated material exhibits retarded mobility in SDS-PAGE and runs as a ladder of bands or a smear. To validate the ubiquitination of candidate substrates in vivo, we generate yeast strains expressing 13×-Myc epitope-tagged candidate substrates and perform the two-step purification protocol on a smaller scale. Western blot analyses of these samples show that the putative Grr1 substrate, Sfg1, is specifically purified as a polyubiquitinated species with the Grr1 ligase trap, but not with two other control ligase traps (Mfb1 and Ufo1) expressed at similar levels (Fig. 2b) . By using the yeast protocol above, we identified 17 known substrates and 18 novel substrates of eight F-box proteins in budding yeast 22 . Our work also demonstrated that ligase traps with different UBAs, Rad23 or Dsk2, performed well in identifying target substrates. Furthermore, we showed that UBAs can be fused to either the N or the C terminus of the F-box protein with little difference in the ability to capture substrate. Figure 3a shows a representative western blot of a β-TrCP ligase trap purification from mammalian cells. A silver stain of the Ni-NTA elution is used to assess purity and yield from each purification (Fig. 3b) .
Using the mammalian protocol, we identified 12 known substrates and 11 new substrates of the human F-box protein β-TrCP 43 . We showed that ligase trapping was an especially accurate method of ubiquitin ligase substrate identification: of the known and candidate substrates that we tested, 88% were either previously described or were validated by us. Grr1-FLRad23
Mfb1-FLRad23
Ufo1-FLRad23 
